Signals, Powered By EquityPandit
Zydus Cadila has received the US health regulator’s approval for marketing Acylovir drug for injection used as an anti-viral chiefly in the treatment of herpes and AIDS.
The company has said in a BSE filing that “Zydus Cadila has received the final approval from the USFDA to market Acylovir for injection USP in strengths of 500 mg/vial and 1000 mg/vial.”
The company has said that it will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
